Technology Bundle ID
TAB-2022

Biological/Research Material for H1N1 Influenza Virus Vaccine Research

Applications
Research Materials
Linked ID
E-260-2009-0
Lead Inventors
Bernard Moss (NIAID)
Co-Inventors
Linda Wyatt (NIAID)
Development Status
Fully developed. The usefulness of the materials has been shown in Dr. Moss' laboratory.
Therapeutic Areas
Infectious Disease
ICs
NIAID
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.

The materials can be used for research purposes and in particular in the area of influenza virus vaccines.

The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.
Commercial Applications
  • Research reagents useful in research and development in the area of H1N1 Influenza virus vaccines.
Competitive Advantages
CB Process - Initiated CB Process. Forwarded email to LPM. Requesting details concerning the new technology.

Request More Info

Licensing Contact: